[go: up one dir, main page]

MX2016001719A - Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular. - Google Patents

Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular.

Info

Publication number
MX2016001719A
MX2016001719A MX2016001719A MX2016001719A MX2016001719A MX 2016001719 A MX2016001719 A MX 2016001719A MX 2016001719 A MX2016001719 A MX 2016001719A MX 2016001719 A MX2016001719 A MX 2016001719A MX 2016001719 A MX2016001719 A MX 2016001719A
Authority
MX
Mexico
Prior art keywords
event
kits
predicting
risk
methods
Prior art date
Application number
MX2016001719A
Other languages
English (en)
Other versions
MX375421B (es
Inventor
Hafid Ait-Oufella
Marc Derive
Sébastien Gibot
Amir Boufenzer
Tabasomme Simon
Nicolas Danchin
Original Assignee
Inotrem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inotrem filed Critical Inotrem
Publication of MX2016001719A publication Critical patent/MX2016001719A/es
Publication of MX375421B publication Critical patent/MX375421B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)

Abstract

La presente invención se refiere a un método para diagnosticar un evento o enfermedad cardiovascular en un individuo al medir el nivel de sTREM-1 en una muestra.
MX2016001719A 2013-08-09 2014-08-08 Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular. MX375421B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361863987P 2013-08-09 2013-08-09
EP14153519.5A EP2835641A1 (en) 2013-08-09 2014-01-31 Methods and kits for predicting the risk of having a cardiovascular disease or event
PCT/EP2014/067120 WO2015018936A1 (en) 2013-08-09 2014-08-08 Methods and kits for predicting the risk of having a cardiovascular disease or event

Publications (2)

Publication Number Publication Date
MX2016001719A true MX2016001719A (es) 2016-06-02
MX375421B MX375421B (es) 2025-03-06

Family

ID=50030127

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016001719A MX375421B (es) 2013-08-09 2014-08-08 Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular.

Country Status (15)

Country Link
US (1) US10948498B2 (es)
EP (2) EP2835641A1 (es)
JP (1) JP6562915B2 (es)
KR (1) KR102266302B1 (es)
CN (1) CN105765382B (es)
AU (1) AU2014304421B2 (es)
BR (1) BR112016002668B1 (es)
CA (1) CA2920652C (es)
ES (1) ES2973810T3 (es)
IL (1) IL244013B (es)
MX (1) MX375421B (es)
NZ (1) NZ716643A (es)
RU (1) RU2721690C2 (es)
WO (1) WO2015018936A1 (es)
ZA (1) ZA201600963B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106053831A (zh) * 2016-06-05 2016-10-26 潘时辉 一种用于自身免疫病检测的试剂盒
FI127416B (en) * 2016-09-29 2018-05-31 Oy Medix Biochemica Ab Cardiovascular risk assessment method
US20210364532A1 (en) 2018-09-28 2021-11-25 Inotrem Use of soluble trem-1 levels for identifying subjects susceptible to respond to an anti-inflammatory therapy
KR102257830B1 (ko) * 2018-12-18 2021-05-28 연세대학교 산학협력단 사망 위험도의 예측 방법 및 이를 이용한 디바이스
BR112022003666A2 (pt) * 2019-09-03 2022-05-24 Somalogic Operating Co Inc Predição de evento de risco cardiovascular e usos da mesma
US20230016187A1 (en) * 2019-11-25 2023-01-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Trem-1 inhibitors for the treatment of vaso-occlusions and tissue injuries in patients suffering from sickle cell disease
JP2023528069A (ja) * 2020-06-05 2023-07-03 イノトレム コロナウイルス感染症罹患対象の重症度又は合併症のマーカーとしての可溶性ｔｒｅｍ－１
CN116507915A (zh) * 2020-06-05 2023-07-28 伊诺特伦公司 可溶性trem-1作为患有冠状病毒感染的受试者的严重程度或并发症的标志物
KR102724742B1 (ko) 2020-12-02 2024-11-01 (주)노보메디슨 선천적 대사질환 위험도 점수를 이용한 심뇌혈관질환의 위험도 측정 방법
EP4304626A1 (en) 2021-03-12 2024-01-17 Institut National de la Santé et de la Recherche Médicale (INSERM) Trem-1 inhibitors for the treatment of marfan syndrome
EP4416501A1 (en) 2021-10-11 2024-08-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of trem-1 for predicting and preventing postoperative complications after cardiac surgery with cardiopulmonary by-pass
WO2025196177A1 (en) 2024-03-21 2025-09-25 Institut National de la Santé et de la Recherche Médicale Use of soluble trem-1 as a biomarker for assessing the risk of cardiovascular disease in asymptomatic subjects

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060084082A1 (en) 1997-03-07 2006-04-20 Human Genome Sciences, Inc. 186 human secreted proteins
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
GB0401730D0 (en) * 2004-01-27 2004-03-03 Bioxell Spa Diagnosis method
CA2675583A1 (en) * 2007-01-16 2008-07-24 Wyeth Inflammation treatment, detection and monitoring via trem-1
CN101821621A (zh) * 2007-07-23 2010-09-01 拜奥克塞尔有限公司 筛选、治疗和诊断
EP2671083A1 (en) * 2011-02-03 2013-12-11 Abbott Laboratories Methods of prognosis and diagnosis in chronic heart failure
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
DK2814844T3 (da) 2012-02-15 2017-11-13 Novo Nordisk As Antistoffer, der binder og blokerer udløsende receptor udtrykt på myeloide celler-1 (trem-1)

Also Published As

Publication number Publication date
CA2920652C (en) 2023-03-07
WO2015018936A1 (en) 2015-02-12
ES2973810T3 (es) 2024-06-24
ZA201600963B (en) 2020-05-27
RU2721690C2 (ru) 2020-05-21
KR20160046828A (ko) 2016-04-29
KR102266302B1 (ko) 2021-06-18
NZ716643A (en) 2020-06-26
MX375421B (es) 2025-03-06
AU2014304421A1 (en) 2016-02-25
CN105765382B (zh) 2019-09-13
CA2920652A1 (en) 2015-02-12
EP3030901B1 (en) 2024-01-10
BR112016002668B1 (pt) 2023-12-12
IL244013A0 (en) 2016-04-21
JP6562915B2 (ja) 2019-08-21
US20160187352A1 (en) 2016-06-30
EP2835641A1 (en) 2015-02-11
AU2014304421B2 (en) 2020-01-16
EP3030901C0 (en) 2024-01-10
JP2016527519A (ja) 2016-09-08
RU2016107954A (ru) 2017-09-14
IL244013B (en) 2020-01-30
EP3030901A1 (en) 2016-06-15
BR112016002668A2 (pt) 2018-01-30
US10948498B2 (en) 2021-03-16
CN105765382A (zh) 2016-07-13

Similar Documents

Publication Publication Date Title
MX2016001719A (es) Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular.
EA201590027A1 (ru) Способы детекции заболеваний или состояний
AR095363A1 (es) Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1
MX355416B (es) Biomarcadores de cancer de pulmon y usos de los mismos.
BR112017009159A2 (pt) métodos e biomarcadores para predizer a eficácia e avaliação de um tratamento com agonista de ox40
MX2017003790A (es) Detección de secuencias diana por percepción de nanoporos de sondas sintéticas.
MX2017008421A (es) Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga.
MX2017015011A (es) Ensayo a base de celulas para detectar homodimeros anti-cd3.
MX340453B (es) Biomarcadores para cancer de pulmon.
EP3411720C0 (en) METHODS OF DIAGNOSIS AND PROGNOSIS OF CARDIOVASCULAR DISEASES AND EVENTS
FR3008805B3 (fr) Procede de determination de mesures oculaires avec un capteur grand public
MX2013014153A (es) Biomarcadores paa terapia de inhibidor de hedgehog.
UY36223A (es) Dispositivos para ensayos, métodos para realizar ensayos, kits para ensayos y método para fabricar dispositivos para ensayos
MX2016006125A (es) Procedimiento, matriz y uso de los mismos.
MX360236B (es) Uso de marcadores en el diagnostico y tratamiento de cancer de prostata.
MX2017006228A (es) Composiciones, dispositivos, y métodos de pruebas de sensibilidad del ibs.
EA201790769A1 (ru) Определение уровней гликозаминогликанов методом масс-спектрометрии
MX2015010174A (es) Herramientas de diagnostico para predecir la presentacion de preeclampsia.
EA201591742A1 (ru) Способ улучшения диагностики заболеваний с использованием измеряемых аналитов
CY1122360T1 (el) Μεθοδος για τη διαγνωση της νοσου niemann-pick
EA201500080A1 (ru) Способ in vitro диагностирования и мониторинга рака
TR201903974T4 (tr) Tasnif makinesi için otomatik kusur tanı metodu ve cihazı.
MX2018005448A (es) Metodos para la deteccion de apolipoproteinas.
ECSP11011376A (es) Dispositivo y procedimiento para la verificación y para el análisis cuantitativo de analitos, particularmente de micotoxinas
MX383423B (es) Método in vitro para el diagnóstico del síndrqme del intestino irritable y la enfermedad inflamatoria intestinal.

Legal Events

Date Code Title Description
FG Grant or registration